IMO -
What have we learnt after covid = To gain wide spread use in the medical field the products need to carry a long list of regulatory approvals against a multitude of bacteria / virus / fungus etc not just a couple of bacteria and covid. Have a look at Clinell and Diversey. Proven efficacy against all of the nasties and much cheaper.
ZNO have suffered the same fate, lack of regulatory approval against all of the nasties and too expensive.
To gain traction in supermarkets it needs to be cheap, cheap cheap. There are plenty of environmental safe and cheap products on the shelf. Why pay so much for an extra 0.00001% kill?
Do we need a focus on regulatory approval and cost reduction to get into the markets that can drive volume sales?
Ann: Preliminary Final Report, page-45
Add SKN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.357M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $2.921K | 730.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 149776 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 1792258 | 5 |
View Market Depth
| Last trade - 10.18am 23/08/2024 (20 minute delay) ? |
| SKN (ASX) Chart |